Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside

Bidram, Elham; Esmaeili, Yasaman; Amini, Abbas; Sartorius, Rossella; Tay, Franklin R.; Shariati, Laleh; Makvandi, Pooyan

doi:10.1021/acsbiomaterials.1c00318

Cited by 27 publications

(23 citation statements)

References 273 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome these restrictions, various nanomaterials have been developed to deliver siRNA in vivo, such as dendrimers, polymers, lipids, iron oxide nanoparticles, silica, and gold nanoparticles. 115 , 116 , 117 Recently, three siRNAs against SARS‐CoV‐2 have been identified through the screening. 118 Simultaneously, two novel lipid nanoparticle delivery systems have also been developed to deliver these siRNAs to the lungs and other organs (Figure 12A,B ).…”

Section: Opportunities For Nanobiotechnology To Contribute To This Fieldmentioning

confidence: 99%

Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology

Bao

Yang

et al. 2022

VIEW

View full text Add to dashboard Cite

Since the outbreak of COVID‐19, the number of confirmed cases and deaths has increased globally at a dramatic speed. In view of the serious health threat to humans, this review discusses the state‐of‐the‐art studies about fighting this disease. It summarizes the current strategies and recent advances in detecting, preventing, and treating COVID‐19 and interprets the underlying mechanisms in detail. Detection of COVID‐19 can be successfully achieved by multiple techniques such as polymerase chain reaction, computed tomography imaging, and nano‐biosensing. Inactivated virus vaccine, nucleic acid vaccine, and different nanoparticles have been employed to effectively prevent COVID‐19. A variety of agents such as antiviral agents, neutralizing antibodies, and nanotherapeutics have been developed to treat COVID‐19 with exciting efficacy. Although nanobiotechnology has shown great potential in the diagnosis, prevention, and treatment of COVID‐19, efforts should be made to explore new biocompatible nano‐biomaterials to advance this field to clinical applications. Hence, nanobiotechnology paves a new way to detect, prevent, and treat COVID‐19 effectively.

show abstract

Section: Opportunities For Nanobiotechnology To Contribute To This Fieldmentioning

confidence: 99%

Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology

Bao

Yang

et al. 2022

VIEW

View full text Add to dashboard Cite

show abstract

“… The effective role of nanoparticles in inhibiting viruses as nano-vaccine components, biosensing, and nanomedicine. Reproduced with permission from [ 33 ]. Copyright American Chemical Society, 2021.…”

Section: Figurementioning

confidence: 99%

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment

et al. 2022

View full text Add to dashboard Cite

Following the announcement of the outbreak of COVID-19 by the World Health Organization, unprecedented efforts were made by researchers around the world to combat the disease. So far, various methods have been developed to combat this “virus” nano enemy, in close collaboration with the clinical and scientific communities. Nanotechnology based on modifiable engineering materials and useful physicochemical properties has demonstrated several methods in the fight against SARS-CoV-2. Here, based on what has been clarified so far from the life cycle of SARS-CoV-2, through an interdisciplinary perspective based on computational science, engineering, pharmacology, medicine, biology, and virology, the role of nano-tools in the trio of prevention, diagnosis, and treatment is highlighted. The special properties of different nanomaterials have led to their widespread use in the development of personal protective equipment, anti-viral nano-coats, and disinfectants in the fight against SARS-CoV-2 out-body. The development of nano-based vaccines acts as a strong shield in-body. In addition, fast detection with high efficiency of SARS-CoV-2 by nanomaterial-based point-of-care devices is another nanotechnology capability. Finally, nanotechnology can play an effective role as an agents carrier, such as agents for blocking angiotensin-converting enzyme 2 (ACE2) receptors, gene editing agents, and therapeutic agents. As a general conclusion, it can be said that nanoparticles can be widely used in disinfection applications outside in vivo. However, in in vivo applications, although it has provided promising results, it still needs to be evaluated for possible unintended immunotoxicity. Reviews like these can be important documents for future unwanted pandemics.

show abstract

“…Nanomedicine represents the state-of-art technology for non-invasive diagnosis and targeted treatment of a host of diseases [ 144 ]. Because of the unique attributes of nanocarriers in promoting the bioavailability of therapeutics, facilitating cellular uptake, and lowering drug resistance and side effects, nanocarriers are regarded as optimal carriers for diagnosis and treatment of viral infections [ 145 ]. To date, a variety of nanocarriers, including lipid-based, polymeric-based, metal-based, and nucleic acid-based carriers have been developed against viral infections [ 146 ].…”

Section: Potential Therapeutics For Management Of Covid-19mentioning

confidence: 99%

The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy

Kouhpayeh

Shariati

Boshtam

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

In late 2019, a new member of the Coronaviridae family, officially designated as “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), emerged and spread rapidly. The Coronavirus Disease-19 (COVID-19) outbreak was accompanied by a high rate of morbidity and mortality worldwide and was declared a pandemic by the World Health Organization in March 2020. Within the Coronaviridae family, SARS-CoV-2 is considered to be the third most highly pathogenic virus that infects humans, following the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Four major mechanisms are thought to be involved in COVID-19 pathogenesis, including the activation of the renin-angiotensin system (RAS) signaling pathway, oxidative stress and cell death, cytokine storm, and endothelial dysfunction. Following virus entry and RAS activation, acute respiratory distress syndrome develops with an oxidative/nitrosative burst. The DNA damage induced by oxidative stress activates poly ADP-ribose polymerase-1 (PARP-1), viral macrodomain of non-structural protein 3, poly (ADP-ribose) glycohydrolase (PARG), and transient receptor potential melastatin type 2 (TRPM2) channel in a sequential manner which results in cell apoptosis or necrosis. In this review, blockers of angiotensin II receptor and/or PARP, PARG, and TRPM2, including vitamin D3, trehalose, tannins, flufenamic and mefenamic acid, and losartan, have been investigated for inhibiting RAS activation and quenching oxidative burst. Moreover, the application of organic and inorganic nanoparticles, including liposomes, dendrimers, quantum dots, and iron oxides, as therapeutic agents for SARS-CoV-2 were fully reviewed. In the present review, the clinical manifestations of COVID-19 are explained by focusing on molecular mechanisms. Potential therapeutic targets, including the RAS signaling pathway, PARP, PARG, and TRPM2, are also discussed in depth.

show abstract

Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside

Cited by 27 publications

References 273 publications

Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology

Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment

The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy

Contact Info

Product

Resources

About